SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. It operates through the Steelmaking and Other Businesses segments. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs stronger-than-guided quarterly results and upbeat 2027 EBITDA outlook have driven a sharp rally, with traders debating whether short covering could extend the move. Bulls see improving steel operations and prices, while skeptics question whether the outlook can overcome the companys debt and reliance on favorable steel markets; some also warn the rally could fade.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras shares are drawing attention amid a steep selloff, with traders pointing to scheduled lockup expirations and potential insider-share supply, alongside concerns about its IPO valuation, growth and ability to scale. The debate pits bearish calls for further declines against dip-buyers who remain bullish on Cerebras AI-inference technology and long-term demand.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

Goldman Sachs Buy upgrade after a sharp selloff is driving attention, but traders are split after the initial pop faded: some see an oversold buying opportunity, while others remain concerned about CoreWeaves heavy debt and financing costs.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius is caught in a broad neocloud and AI-infrastructure selloff as traders focus on financing costs, debt concerns and doubts about the sectors business models, with CoreWeaves credit worries adding to contagion fears. The community is split on whether sharp rebounds are durable or bull traps: bulls point to Nebiuss comparatively stronger balance sheet and long-term compute demand, while bears question the capital intensity and path to profitability.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea shares are under pressure after a prolonged decline, with traders frequently blaming insider share sales and frustration that management has not announced a fresh buyback. Some see the selloff as a buying opportunity given the companys growth and cash position, while others warn the stock may keep falling and question its valuation and management.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

FDA expanded ANKTIVA plus BCG to cover papillary-only BCG-unresponsive bladder cancer, broadening its potential market; traders also focused on long-term Phase 3 data showing durable responses and bladder-sparing outcomes. Despite bullish views on the commercial opportunity, the shares sold off, with the community debating a sell-the-news reaction and broader biotech weakness versus options-related or short-selling pressure, while some remain cautious about revenue growth and dilution.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

XEs steep selloff and search for a bottom dominate the discussion, with traders attributing pressure to post-IPO selling, bearish analyst coverage, and weakness across nuclear stocks. Some see Amazons backing and potential SMR demand from data centers as a long-term positive, while others remain concerned that commercialization is years away.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Taus cancer-trial pipeline is driving attention, particularly the FDA-cleared expansion of its recurrent glioblastoma REGAIN study and completed enrollment in the pancreatic IMPACT study ahead of further data updates. Traders are broadly optimistic about these milestones, though expectations for a near-term stock move remain speculative amid price consolidation.

Almonty Industries, Inc. engages in the mining, processing, and shipment of tungsten concentrates. Its projects include Almonty Korea Tungsten, Panasquiera mine, Gentung, Almonty Korea Moly, Los Santos mine, and Valtreixal. The company was founded on September 28, 2009 and is headquartered in Dillon, MT.

Almonty Industries Inc

ALM is drawing attention after a sharp selloff during and following its investor day, with traders criticizing CEO Lewis Blacks presentation and questioning whether it offered meaningful new information. The reaction contrasts with longer-term bullish views on Sangdongs production ramp and tungsten demand, while some attribute weakness to broader market pressure.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is drawing attention ahead of its Q3 earnings report as shares retreat amid a broader tech and AI selloff. Traders are split over whether strong ad performance and Muse AI momentum can justify heavy AI spending, with capex and returns on that investment central to expectations for the report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Reported takeover interest in Xeris, widely attributed by traders to Lundbeck, has fueled buyout and possible bidding-war speculation, though no deal is confirmed and the company has said it is not for sale. The community is divided between focusing on the rumor-driven momentum and valuing Xeriss Recorlev growth and XP-8121 pipeline prospects as a standalone business.

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced clinical and scientific data presentations from its...

Full Transcript: Xeris Biopharma Holdings Q2 2026 Earnings Call

Xeris Biopharma Holdings (NASDAQ:XERS) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below.
This content is powered by Benzinga APIs. For comprehensiveread more...

Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on October 1, 2026, the Compensation Committee of Xeris Board of...

Xeris Biopharma Reportedly Draws Takeover Interest — But Firm Says It’s ‘Not For Sale’

Equity

According to a Bloomberg report, Danish company Lundbeck has been working with advisers to explore a potential takeover of Xeris.

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, will host an XP-8121 Program Overview today at 10 a.m. ET detailing a comprehensive...

Xeris Announces Details for XP-8121 Program Overview Webinar

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced details for a dedicated Program Overview webinar for XP-8121, the Companys...

Compared to Estimates, Xeris Biopharma (XERS) Q2 Earnings: A Look at Key Metrics

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Xeris Biopharma Reports Second Quarter 2026 Financial Results

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced its financial results for the second quarter ended June 30, 2026. "The...

Zevra Therapeutics (ZVRA) Q2 Earnings and Revenues Surpass Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of +212.50% and +22.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Xeris Biopharma to Report Second Quarter 2026 Financial Results on August 6, 2026

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the Company will release its second quarter 2026 financial results...

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Bearish Sentiment

<ul class="summary-bullets"><li>Xeris’s lead pipeline candidate for hypothyroidism could fetch between $1 billion and $3 billion annually.</li><li>Xeris focuses on endocrine and rare diseases and currently sells three treatments.</li><li>The company had $121.7 million in cash and cash equivalents as of the end of June.</li></ul>Xeris Biopharma (<a class="mention" data-mention="$XERS" data-symbol-id="XERS" href="https://stocktwits.com/symbol/XERS" target="_blank">XERS</a>) was in focus on Tuesday after Danish drugmaker Lundbeck reportedly expressed interest in acquiring the Chicago-based biotech firm focused on rare-disease treatments.According to a Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-09-29/lundbeck-is-said-to-express-interest-in-buying-xeris-biopharma">report</a> on Tuesday, Lundbeck has been working with advisers to explore a potential takeover, though there is no guarantee the interest will result in a deal.Xeris told Bloomberg that the company is “not for sale” and remains “laser focused” on developing and commercializing its medicines.<a href="https://stocktwits.com/symbol/XERS">XERS shares</a> surged more than 15% after the report was published but quickly pared the gains and turned negative. The stock is now trading around 2% lower.<h2 class="st-heading-2">A Look At Xeris’ Pipeline</h2>Xeris focuses on endocrine and rare diseases and currently sells three treatments, including Recorlev for Cushing’s syndrome, Gvoke for severe low blood sugar, and Keveyis for primary periodic paralysis, a rare disorder that causes episodes of muscle weakness or paralysis.Beyond its marketed products, Xeris’ pipeline is led by XP-8121, an experimental once-weekly injection for hypothyroidism.The company has announced plans to begin a Phase 3 study by year-end, with topline results expected in late 2028 and a potential U.S. launch in 2030. Xeris <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.xerispharma.com/news-releases/news-release-details/xeris-hosts-webinar-detailing-its-comprehensive-development">estimates</a> the treatment could eventually generate $1 billion to $3 billion in peak annual revenue.<h2 class="st-heading-2">Recorlev Drives Q2 Topline Growth</h2>The company posted a 29% jump in second-quarter (Q2) revenue to $92.1 million. Product revenue rose 34% to $91 million, driven largely by Recorlev, whose sales surged 81% to $56.8 million.Xeris reported a net loss of $31.1 million, or $0.18 per share, partly due to a $31 million non-cash charge related to a debt exchange. The company had $121.7 million in cash and cash equivalents as of the end of June.<h2 class="st-heading-2">Retail Turns ‘Extremely Bullish’ On <a class="mention" data-mention="$XERS" data-symbol-id="XERS" href="https://stocktwits.com/symbol/XERS" target="_blank">XERS</a></h2>Retail sentiment for <a class="mention" data-mention="$XERS" data-symbol-id="XERS" href="https://stocktwits.com/symbol/XERS" target="_blank">XERS</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours, amid ‘extremely high’ message volumes. <a class="mention" data-mention="$XERS" data-symbol-id="XERS" href="https://stocktwits.com/symbol/XERS" target="_blank">XERS</a> was also among the top trending stocks on the platform.One user said, “Even if it’s not Lundbeck, we know the conversations are happening now.”<stembedurl>https://stocktwits.com/TymeTryethTroth/message/665351581</stembedurl>The stock has gained around 33% so far this year.Also read: <a href="https://stocktwits.com/news-articles/markets/equity/bofa-raises-immix-price-target-after-clinical-trial-result/cZMZ7RQRBWI">BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

SPDR S&P Biotech ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$10.84
Prev Close	$10.31
Open	$10.40
Dividend Yield	0.00%
50-Day Moving Average	$8.86
Beta	1.14
Avg. Volume	3.02M
PE Ratio	-100.78

52-Week High	$11.33
52-Week Low	$5.25
Market Capitalization	$1.88B
EPS (Annual)	$0.0032
Price to Book	-183.88
Revenue Per Employee	$670,908.05

Feed

News

Sentiment

Earnings

Fundamentals

Info

XERS Fundamentals